Clinical Trials Directory

Trials / Unknown

UnknownNCT06200376

A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer

A Clinical Study of Safety and Efficacy of T3011 Administered Via Intraperitoneal Injection as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
West China Hospital · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This is a prospective, open, single-arm, investigator-initiated clinical study to evaluate the safety and efficacy of intraperitoneal administration of T3011 at different doses in the treatment of malignant ascites induced by advanced colorectal cancer.

Conditions

Interventions

TypeNameDescription
DRUGT3011T3011 will be administered intraperitoneally twice a week.

Timeline

Start date
2023-09-28
Primary completion
2024-12-01
Completion
2024-12-01
First posted
2024-01-11
Last updated
2024-01-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06200376. Inclusion in this directory is not an endorsement.

A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced (NCT06200376) · Clinical Trials Directory